Anadys Initiates Dosing in Phase I Cancer Trial
Posted on: Friday, 29 February 2008, 09:01 CST
Anadys Pharmaceuticals has commenced patient dosing in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors.
The Phase I trial, a multiple, ascending dose study conducted at several sites in the US is designed to identify pharmacologically active doses and preliminary antitumor activity as well as to select the dose and schedule for Phase II trials. In addition to safety and tolerability, patients will be monitored for pharmacodynamic responses indicative of immunological stimulation. Initially, patients will be dosed every other day. The company also expects to investigate additional schedules during this first clinical trial and anticipates that up to 60 patients will be enrolled in the study.
Steve Worland, president and CEO of Anadys, said: "The initiation of this trial marks the resumption of our clinical investigation of oral TLR7 agonists and moves us closer toward our objective of developing ANA773 as a novel therapy for patients with cancer."
Source: Datamonitor
Related Articles
- Oncothyreon Initiates Enrollment for Phase I Trial of Tumor Drug
- Oncothyreon Initiates Phase 1 Trial of PX-866 Cancer Compound
- NeoPharm Enrolls First Patient in Phase I Trial for Patients With Metastatic Solid Cancer
- Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-Related Macular Degeneration
- ZIOPHARM Treats Patients in U.S. Phase I Trials of Oral Darinaparsin and Indibulin
- Medivation Announces Treatment of First Patient in Phase 2 Trial of Dimebon(TM) in Huntington's Disease
- SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor
- Depomed Initiates Dosing of Patients in Phase 2 Trial For Gabapentin GR For the Treatment of Menopausal Hot Flashes
- Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
- Poniard Doses First Patient in Phase I Trial
 |
 |
User Comments (0)
RSS Feeds